
White House Announces Action to Increase Competition, Decrease Cost of Biosimilar Development
Leaders of the FDA, the US Department of Health and Human Services, and the Centers for Medicare & Medicaid Services announce new guidelines and a framework for less expensive biosimilar development.





























